EPF Acknowledgement of Financial Support in 2023
Funding Transparency (Jan - Dec 2023)
| Public Contribution 2023 | % of total income | |
| TOTAL European Commission support to projects 2023 | € 619.982,58 | |
| Core MD | € 23.887,38 | 1,1% |
| ComparEU | € -15.000,76 | -0,7% |
| EATRIS + | € 51.577,85 | 2,3% |
| EHDEN | € 106.954,50 | 4,8% |
| EU-PEARL | € 117.364,39 | 5,2% |
| Gravitate Health | € 63.423,70 | 2,8% |
| H2O | € 77.055,65 | 3,4% |
| HTA360 | € 5.635,96 | 0,3% |
| IMMUCAN | € 29.114,40 | 1,3% |
| LABEL To ENABLE | € 56.407,99 | 2,5% |
| PERISCOPE | € 37.876,84 | 1,7% |
| EUCAPA | € 23.816,76 | 1,1% |
| IDERHA | € 12.075,48 | 0,5% |
| PROPHET | € 18.890,54 | 0,8% |
| HEU-EFS | € 10.901,90 | 0,5% |
| Access to Medicine | - € 6.000 | |
| Membership Income | ||
| Membership fees | € 28.850,00 | 1,3% |
| EPF wishes to thank the following donors for their support: | ||
| Contribution to Operations | % of total income | |
| Operational & Engagement - Work Plan 2023 | € 640.000,00 | |
| Abbvie SA | € 35,000.00 | 1.6% |
| Amgen Inc | € 25,000.00 | 1.1% |
| Baxter World Trade SPRL | € 10.000,00 | 0.4% |
| Boehringer Ingelheim International | € 35.000,00 | 1,6% |
| Bosch Health Campus | € 10.000,00 | 0,4% |
| Bristol Myers Squibb | € 60.000,00 | 2,7% |
| Chiesi Farmaceutici S.p.A | € 25.000,00 | 1,1% |
| Edwards Lifesciences SA | € 25,000.00 | 1,1% |
| EFPIA | € 25.000,00 | 1,1% |
| F. Hoffmann-La Roche Ltd | € 60.000,00 | 2,7% |
| GlaxoSmithKline | € 30.000,00 | 1,3% |
| Horizon Therapeutics | € 35.000,00 | 1,6% |
| Intuitive Surgical Sàrl | € 10.000,00 | 0,4% |
| Medicines for Europe | € 20.000,00 | 0,9% |
| Novartis Pharma AG | € 80.000,00 | 3,6% |
| NV Janssen Pharmaceutical | € 50.000,00 | 2,2% |
| Pfizer INC | € 40.000,00 | 1,8% |
| Sanofi-Aventis Group | € 50.000,00 | 2,2% |
| UCB Biopharma SPRL | € 15.000,00 | 0,7% |
| Capacity Building Programme 2023 HTA - Artificial Intelligence - PEOF - DSL | € 581.942,53 | |
| Contribution to the CBP and others | % of total income | |
| Capacity Building Programme | ||
| Daiichi Sankyo Europe GmbH | € 30.000,00 | 1,3% |
| GlaxoSmithKline | € 30.000,00 | 1,3% |
| Horizon Therapeutics | € 40.000,00 | 1,8% |
| Institut La Conference Hippocrate | € 20.000,00 | 0,9% |
| Merck Sharp & Dohme Corp. | € 54.323,52 | 2,4% |
| Novavax GmbH | € 15.000,00 | 0,7% |
| Novocure Inc | € 40.411,01 | 1,8% |
| Novo Nordisk Denmark A/S | € 26.000,00 | 1,2% |
| Takeda Pharmaceuticals International | € 20.000,00 | 0,9% |
| HTA Capacity Building Simulation Workshop | ||
| Astellas Pharma Europe Ltd. | € 10.000,00 | 0,4% |
| Msd Belgium Bv | € 30.000,00 | 1,3% |
| Novartis Pharma AG | € 10.000,00 | 0,4% |
| Pfizer INC | € 20.000,00 | 0,9% |
| Takeda Pharmaceuticals International | € 10.000,00 | 0,4% |
| Artificial Intelligence | ||
| European Artificial Intelligence & Society Fund | € 83.250,00 | 3,7% |
| PEOF | ||
| The Synergist Asbl | € 25.458,00 | 1,1% |
| DSL | ||
| Aisbl Medtech Europe | € 10,000.00 | 0,4% |
| EFPIA | € 50.000,00 | 2,2% |
| F. Hoffmann-La Roche Ltd | € 25.000,00 | 1,1% |
| Novartis Pharma AG | € 5.000,00 | 0,2% |
| Takeda Pharmaceuticals International | € 20.000,00 | 0,9% |
| Netherlands Patients' Federation | € 7.500,00 | 0,3% |
| EPF 20th Anniversary Event 2023 | € 378.375,39 | |
| Aisbl Medical Nutrition International Industry | € 10.000,00 | 0,4% |
| Baxter World Trade SPRL | € 10.000,00 | 0,4% |
| Boehringer Ingelheim International | € 10.000,00 | 0,4% |
| Bosch Health Campus | € 10.000,00 | 0,4% |
| EFPIA | € 10.000,00 | 0,4% |
| F. Hoffmann-La Roche Ltd | € 25.000,00 | 1,1% |
| Galapagos NV | € 20.000,00 | 0,9% |
| Grünenthal Gmbh | € 5.000,00 | 0,2% |
| H. Lundbeck A/S | € 10.000,00 | 0,4% |
| Horizon Therapeutics | € 15.000,00 | 0,7% |
| Intuitive Surgical Sàrl | € 10.000,00 | 0,4% |
| IQVIA Ltd | € 10.000,00 | 0,4% |
| Merck | € 40.000,00 | 1,8% |
| Merck Sharp & Dohme Corp. | € 19.375,39 | 0,9% |
| Novartis Pharma AG | € 20.000,00 | 0,9% |
| Novavax GmbH | € 20.000,00 | 0,9% |
| NV Janssen Pharmaceutica | € 20.000,00 | 0,9% |
| Pfizer INC | € 10.000,00 | 0,4% |
| Servier Affaires Medicales | € 20.000,00 | 0,9% |
| Takeda Pharmaceuticals International | € 40.000,00 | 1,8% |
| UCB Biopharma SPRL | € 10.000,00 | 0,4% |
| Vertex Pharmaceuticals (Europe) | € 14.000,00 | 0,6% |
| Viatris | € 20.000,00 | 0,9% |
| Other income (including reverses) | € 21.983,23 | |
| Other income | € 21.983,23 | 1% |